Directory · FR
Biotechnology in France
A register of firms and the professionals working at them in the Biotechnology sector based in France. Browse the public index, then filter or export on Kipplo.
Companies
270 on file
Genfit
GENFIT, a BCorp™ certified company since 2025, is a biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on compartment B of Euronext’s regulated market in Paris ( Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.
51 to 200 staff
Devyser
Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.
51 to 200 staff
Greentech
Our Credo We are biotech pioneers, we are scientists, we are explorers. Working across all continents, in all climates, in all of the worlds’ oceans. We create high-tech active ingredients from natural sources from plant, marine and microbial worlds. We source the best that nature has to offer, to the benefit of everyone: in cosmetics, healthcare, human and animal nutrition, agronomy and environment. We operate worldwide to build sustainable subsidiaries that are founded on the principles of protecting biodiversity and human relationships. No nature, no future! Nature is a source of inspiration, source of information, the source of our technologies. We source nature to resource the future. Wo We Are Pioneer in biotechnology, GREENTECH Group creates high-tech active ingredients from natural sources from plant, marine and microbial worlds. Adressed to major markets (cosmetics, healthcare, human & animal nutrition, agronomy and environment) the GREENTECH Group’s innovations represent proven, healthy and sustainable alternatives, serving future generations.
51 to 200 staff
Abbelight
Founded in 2016, Abbelight is a fast-growing company specialized in imaging solutions focusing on microscopy and unique single molecule detection (super-resolution). The portfolio integrates a constantly evolving knowhow on chemistry, optics and computer science to offer a complete solution, from sample preparation to data management, including an optimal bio-imaging platform that can be adapted to all researchers’, biotech labs’ and medical facilities’ needs. Abbelight is a French company developed by four passionate researchers who aim to help improve human health in various areas such as bacteriology, extracellular vesicles, neurosciences, structural biology. Today, Abbelight employs over 60 people who are all driven by the goal of providing the best solutions and support to our customers all around the Créée en 2016, Abbelight est une société en forte croissance spécialisée dans le développement de solutions complètes de microscopie et de nanoscopie (SMLM). Son portfolio intègre un savoir-faire en constante évolution alliant la chimie, l’optique et l’ingénierie informatique. Ainsi, la plate-forme de bio-imagerie proposée permet aux chercheurs des instituts de recherche publiques et aux biotechs, d’optimiser leurs préparations d’échantillons, l’acquisition et la gestion de leurs données grâce à un panel de techniques avancées adaptées à différentes applications. Abbelight est une société française fondée par quatre chercheurs passionnés, qui s’engage à contribuer à l’amélioration de la santé humaine dans de nombreux domaines tels que la bactériologie, les vésicules extracellulaires, les neurosciences, la biologie structurelle… Aujourd’hui, Abbelight emploie plus de 60 collaborateurs, tous animés par la volonté de fournir les solutions de recherches innovantes et d’accompagner ses clients à travers le monde.
11 to 50 staff
Alliance Bio Expertise
ALLIANCE BIO EXPERTISE crée, fabrique et distribue des solutions innovantes pour les laboratoires du monde entier, dans les domaines de la microbiologie et de l'environnement contrôlé. Jour après jour, l'équipe ABE met toute son expérience et son expertise à votre service, pour vous offrir des solutions sur-mesure et clef en main dans les secteurs cosmétique, agro-alimentaire, pharmaceutique, clinique, ainsi que la recherche. Vos challenges sont nos solutions!
11 to 50 staff
Erbc
ERBC is a 50 years’ leading CRO committed to bridge the gap between preclinical and clinical research by better predicting the efficacy and safety of new compounds offering innovative in vitro and in vivo translational models and services. Offering a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services, ERBC allows biopharmaceutical and chemical industry professionals to de-risk innovation and enhance R&D productivity. With highly qualified teams, ERBC is offering a customer-centric approach while committed in improving all aspects of study design and conduct applying alternatives to animal testing as a priority.
201 to 500 staff
Andermatt France
Jardiner, cultiver avec des solutions respectueuses de notre environnement Andermatt France est une PME franco-suisse innovante dédiée à 100% au Biocontrôle et à l'Agriculture Biologique. Nous concevons, fabriquons et mettons en marché des solutions alternatives à la chimie conventionnelle pour l'agriculture, les jardins et les espaces verts pour les professionnels et les particuliers. Notre ambition : remplacer les produits de la chimie de synthèse (pesticides, engrais ou biocides) par des alternatives d'origine naturelle. Notre recherche est au service d'une alimentation saine, dans un environnement préservé.
11 to 50 staff
Astraveus
We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies.
51 to 200 staff
Cellenion
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single-cell isolation and bioprinting : Ability to manipulate single-cell has long been a challenge for the scientific community due to their micrometric size and delicate nature. Cellenion has developed and patented CellenONE, a breakthrough single cell isolation and dispensing technology. CellenONE provides outstanding single cell precision, high throughput, and unmatched recovery. Bioprinting is the process of generating spatially-controlled cell patterns using 3D printing technologies. Cellenion will aim toward both miniaturization and automation in order to produce reproducible models of different complexities.
11 to 50 staff
Transgene
Cancer immunotherapy Transgene (Euronext: TNG) is a clinical stage biotechnology company focused on individualized therapeutic vaccines
51 to 200 staff
Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
51 to 200 staff
Ariana Pharma
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.
11 to 50 staff
Biomemory
Biomemory is a deep-tech company specialized in enterprise data storage. It leverages molecular engineering to build cost-effective and energy-efficient exabyte rackable appliances for Data Centers. Biomemory also develops high-quality DNA-based anti-counterfeiting systems with minimal ecological impact. Contact us: contact@biomemory.com Jobs and internships: jobs@biomemory.com
11 to 50 staff
Fermentalg
About Fermentalg: Based in Libourne (France), Fermentalg is an industrial biotechnology company, specialized in the production of oil rich in fatty acids (omega-3), proteins and natural pigments (phycocyanin) by fermentation of microalgae. Fermentalg offers innovative products in the global market such Food, Feed and Environment. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, À propos de Fermentalg : Basée à Libourne (France), Fermentalg est une société de biotechnologie industrielle, spécialisée dans la production d’huiles riche en acides gras (oméga-3), de protéines et de pigments naturels (phycocyanine) par fermentation de microalgues. Fermentalg propose des produits innovants pour les marchés mondiaux tel que l’alimentation humaine et animale et l'environnement. L’action Fermentalg est cotée sur Euronext à Paris (FR0011271600 - FALG). Plus d’informations :
51 to 200 staff
Grosseron Sas
L’activité de Grosseron est essentiellement basée sur le négoce et la distribution d’équipements, consommables, réactifs et mobiliers de laboratoire. Nous sommes devenus l’un des acteurs majeurs dans ce domaine et réalisons plus de 50 millions d’Euros de chiffre d’affaires. Nous travaillons avec plus de 500 fournisseurs et tenons en stock plus de 100 références réparties en huit gammes spécifiques - Matériel - Produits chimiques - Microbiologie - Biotechnologies - HACCP - Hygiène et sécurité - Mobilier - Prélèvement Grosseron est une entreprise connectée, agile, capable de s'adapter en permanence aux attentes de ses clients et fournisseurs, et ce depuis 130 ans.
51 to 200 staff
Groupe Carso
Leader des prestations analytiques environnementales et agroalimentaires accrédité COFRAC, agréé par le Ministère de la santé Votre environnement et votre santé sont nos priorités. MISSIONS :+ Préserver la santé et contrôler notre environnement. Faire que la population ne court aucun danger dans sa consommation quotidienne et son environnement.+ Travailler en partenariat avec les Agences régionales sanitaires, les agences de l'eau, la grande distribution. DESCRIPTION :+ Matrice Eaux de consommation et sanitaires + Matrice des produits agro alimentaires que vous consommez + Matrices de l'air que vous respirez + Matrice sols + Analyse génétique sur les scènes de crime "section médico légale"+ Analyse des substances dangereuses + Analyse des OGM + Analyse des Dioxines + Analyse Hallal "recherche de présence de porc dans les aliments par génétique"+ Analyse de la radioactivité + Analyse des maladies génétiques + Essais Ecotox, Matériaux aux contacts de l'eau, amiante, Traces organiques, inorganiques.
1001 to 5000 staff
Inovotion
INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies. Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage. This breaking-thought technology, based on chick embryo, provides early analysis of your treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs. It’s rapid Go/No Go decision with multi-cancer screening capacities. This next generation of in vivo efficacy and toxicity tests covers fours main aspects- EFFICACY assays for your anti-cancer treatments - EARLY TOXICITY assays for your drug candidates - TARGET VALIDATION in oncology - MULTI-CANCER SCREENING to (re)positioning your treatment We help chemists and biologists from companies and universities to validate a target and develop treatments by getting them through in vivo evaluation, while staying within their budget. These accessible efficacy and toxicity assays open really new perspectives of screening for wide variety of project researches with a rapid Go/No Go decisions. You want focus your R&D on your high-value molecules, contact us!
11 to 50 staff
Mabqi
Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities.
11 to 50 staff
Phaxiam Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
51 to 200 staff
Phoenix Pharmaceuticals, Inc
Phoenix Pharmaceuticals is a business-to-business (B2B) peptide wholesaler. We manufacture ELISA kits, Peptides, Antibodies and provide Custom Peptide Synthesis. All products made at our laboratory in Silicon Valley, CA. Our customers are scientific researchers, academic labs, and biotech/pharma doing preclinical research and drug development.
11 to 50 staff
Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
11 to 50 staff
Aqualeha
Avec ses expertises, AQUALEHA vous propose une palette de services pour prévenir l’ensemble des risques alimentaires, de sécurité ou environnementaux pour la protection des biens et des personnes.
201 to 500 staff
Biodevas Laboratoires
Recherche, développement et commercialisation des solutions naturelles. Secteur d’activité: Production végétale et animale. Nos produits sont à base des extraits de plantes aromatiques. Mode d'action: Gestion des stress abiotiques et biotiques par une régulation enzymatique. Intérêt: Réduction des intrants chimiques de protection. Profile: Sans résidus, sans délai avant récolte ou d’abattage, utilisable en agriculture biologique.
11 to 50 staff
Aviwell
Aviwell operates at the convergence of DIGITAL & LIFE SCIENCES. Our mission is to develop natural and sustainable solutions to improve animal health to better nourish and provide FOOD SECURITY to the nearly 8 billion people on our planet. And to do so a fraction of the cost. We are a deep-tech startup with our HQ in Toulouse, France and with sales offices in Boston, USA. The company is based on three disruptive assets: • Proprietary biostatistical algorithms, • Extensive microbiology and physiology expertise, and • Native and Adaptive Biomimicry When combined, we are able to develop revolutionary feed solutions for farmers that significantly improve animal growth and health. Aviwell aims to market these unique products on a global market.
1 to 10 staff
Eden Tech
EDEN TECH is a young innovative company founded in 2017, providing innovators with original microfabrication solutions to boost your R&D and commercialize your microfluidic technologies. Our R&D departments, Eden Cleantech and Eden Medtech, focus on the development of new microfluidic technologies inspired by nature."Ascandra" is our microfluidic based technology for microplastics filtrations, and "AKVO" is for micropollutants. These technologies are being developed to process high volumes of fluids, while maintaining low energy consumption. Eden Tech is also working on a Green Hydrogen Project as well as MedTech projects. It is driven by an international team of scientists and entrepreneurs. All together, we assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems.
11 to 50 staff
Everzom
EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver. Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field. The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.
11 to 50 staff
Kolibri
Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly.
1 to 10 staff
Otr3
OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on RGTA® (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates. After an injury, RGTA® target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and corneal ulcers. OTR3's Pipeline include innovative therapeutic products for ischemic stroke (Project awarded a H2020 SME Instrument grant), Acute respiratory distress syndrome (ARDS) and chronic ulcer for epidermolysis bullosa (Project awarded a PIA Leader Innov'Up grant).
11 to 50 staff
Bio Support
BIO SUPPORT est un groupement d'employeurs spécialisé dans le domaine des biotechnologies. L'association, sous forme de loi 1901 a été créée en 2006 à l’initiative d’un groupe de 6 jeunes sociétés soutenues par GENOPOLE ENTREPRISES. Aujourd’hui BIO SUPPORT : Ce sont 15 salariés mis à disposition dans plus de 30 entreprises. BIO SUPPORT est membre de l’UGEF.
11 to 50 staff
Bioteos
Soucieux des enjeux environnementaux et sanitaires actuels, Bioteos a pour ambition d’allier nature et technologie au service de l’Humain. 🤝 Nous avons donc développé OXYLON, un puits carbone reposant sur l’immense potentiel des microalgues afin de purifier l’air ambiant. 🧪
1 to 10 staff
Core Biogenesis
The future of recombinant protein bioproduction.
11 to 50 staff
Covalab
Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website. The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the scientists at CovalAb have more than 30 years of experience in the chemical modification of antigens and antibodies destined for diagnosis and therapy. A list, by no means complete of some of their achievements- In biomedicine, includes the production of: antibodies directed against new tumour markers, antibodies as gene vectors in cancerology, antibodies reacting specifically with cerebral protein aggregates in neurology, diagnostic kits for detecting patients with autoimmune disease such as rheumatoid arthritis and celiac disease- In agro-food, the development of complete diagnostic kits including the antibodies and the chemically modified immunogens for the detection of mycotoxins, phycotoxins, pesticides and polyaromatic hydrocarbons. Our mission is to give to researchers every day high quality antibodies and powerful tools to accelerate your research and move on to discovery. We help our clients to face new challenges in biology and to improve life thanks to translational research, personalized medicine, stem cell therapy and food safety.
11 to 50 staff
Deeplife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
11 to 50 staff
Elicityl
Elicityl is a biotechnology company based near Grenoble France within one of the largest research clusters in Glycosciences in the world. Elicityl is specialized in carbohydrates design & manufacturing and has unique expertise in extraction, purification, bacterial fermentation, characterization, and analysis of carbohydrates. Our catalog of products, which is constantly evolving, includes: 200 glycans involved in key biological pathways (Cell adhesion, Immunological recognition, Embryogenesis, Oncogenesis, Infection…) Analytical references (HMOs, Malto-Oligosaccharides, Fructo-Oligosaccharides…) Polysaccharides extracted from biomass (Alginate, Ulvan, Pustulan…) Functionalized glycans Glycoconjugates Lectins We supply materials from the mg scale up to the multi-100 grams scale. We also evaluate specific needs to provide customized solutions. We propose R&D and analytical services, in several fields of application such as: Plant protection products Animal nutrition Anti-infectious compounds Medical devices Our laboratory is composed of constantly evolving and complementary platforms: A pilot plant enabling semi-industrial carbohydrate production by extraction from biomass A Biofermentation platform (with more than 150 bacteria strains) that allows the production in large amounts of very complex and bioactive oligosaccharides such as Human Milk Oligosaccharides (HMOs), Tumor-associated carbohydrate antigens (TACA), … A glycochemistry laboratory to functionalize or graft carbohydrates A platform for pre-purification and fine purification An analytical platform including: HPAEC-PAD, HPLC-ELSD, 1H-NMR and 13 C-NMR 400 MHz, Mass spectrometry (MALDI-TOF and ESI), LC-MS, associated to human expertise We look forward to discussing your needs and becoming a partner for your future projects. Do not hesitate to contact us by LinkedIn or by mail contact@elicityl.fr
11 to 50 staff
Algo Paint
Algo révolutionne le marché de la peinture. Les peintures Algo apportent une alternative réelle à la chimie du pétrole en valorisant les végétaux et particulièrement les algues. Les matières premières sont donc locales et régionales ce qui permet de valoriser une filière courte. En rupture avec les peintures classiques, Algo est donc la seule peinture fabriquée à base de végétaux et est composée à 98% de ressources bio-sourcées quand les peintures classiques contiennent 65 à 75% d'éléments d'origine pétrolière. Notre gamme de peinture répond bien évidemment aux normes environnementales les plus exigeantes (un taux 10 fois inférieur aux normes les plus strictes concernant la qualité de l'air intérieur des logements). De plus, nos peintures contiennent moins d'un gramme de C.O.V. par litre (composés organiques volatiles) ce qui permet de préserver de la qualité de l'air tout en rendant notre peinture inodore. Pour en savoir plus : https://twitter.com/AlgoPeinture
1 to 10 staff
Atlantic Bone Screen
Atlantic Bone Screen is a leading CRO (« Contract Research Organization ») specialized in high-quality preclinical evaluation services in the field of inflammation, osteoarticular diseases and skin diseases. Thanks to its high expertise, Atlantic Bone Screen evaluates drug candidates, biomaterials (either for orthopedic or dental applications) and ingredients/products for cosmetics and food industry. We provide high-quality services to support the characterization of drug candidates, nutraceuticals, biomaterials. Located in Nantes, North-West of France and created in 2005, Atlantic Bone Screen puts at your disposal a unique preclinical platform with a wide range of assays- In vitro assays: Primary cells and cell lines from human and/or animal origin: osteoclasts, osteoblasts, macrophages or chondrocytes, tumor cell lines - In vivo assays: Reliable animal models (rats, mice, rabbits, sheeps) reproducing human bone pathologies (Osteoporosis, Arthritis, Rheumatoid arthritis, Bone cancer.)/ we have our own rodent animal facilities - Histology/Histopathology (hard and soft tissue):* Embedding (paraffin, resin, frozen)* Chromogenic staining and Immunostaining of tissue markers (IHC and IF)* Histopathology and image analysis (tissue parameters or components)* Multi-organ toxicity studies, experimental model analysis,… - Imaging services: microCT, and X-Ray analyses Get in touch with us for additional information and request! And also discover our Sister Company- ATLANTHERA, drug discovery company in bone research -
11 to 50 staff
Cryocapcell
Created in 2013, CryoCapCell® designs, develops and globally markets the CryoCapsule®: a unique, proprietary technology for high-pressure vitrification. CryoCapCell constantly innovates to make your Correlative Light and Electron Microscopy experiments faster, simpler and more reliable. Thanks to the highly innovative nature of its technologies, CryoCapCell has developed partnerships with leading scientific research institutions, including Institut Curie and the Mechanical and Materials Engineering Laboratory (PIMM) at Arts et Métiers.
1 to 10 staff
Metagenopolis
MetaGenoPolis (MGP) is an INRAE unit expert in gut microbiome research applied to human and animal health and nutrition, funded by the Programme des Investissements d'Avenir (Laureate 2012 and 2019). MGP's expertise in the analysis of the gut microbiome and its implications for health and nutrition has been widely recognized in the international scientific community since 2010. In collaboration with industry, academia and clinics, MGP conceives and implements projects tailored to the partner’s need. ISO 9001 certified, the protocols and procedures are constantly maintained at the cutting edge of technology. To explore the link between the microbiome, nutrition and health, MGP has innovative technological platforms accompanied by an ethical center UCLy (Catholic University of Lyon). MGP offers end-to-end microbiome analysis services, including DNA extraction, library preparation, shotgun sequencing, quantitative and functional metagenomics, big data storage and computing facilities, bioinformatics, statistical analysis, and data interpretation. One of MGP's ambitions is to create, via a citizen science project, a public database of the gut microbiomes of French individuals, one of the objectives of which will be to better understand the heterogeneity of the gut microbiome of healthy French people. MGP also aims to develop more industrial partnerships and the creation of start-ups to accelerate microbiome science and innovation in health and nutrition
51 to 200 staff
Sparingvision
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit
11 to 50 staff
Aurea Agrosciences
AUREA est le leader Français des analyses agronomiques et agro-environnementales. Acteur majeur et reconnu dans les domaines de l’agronomie et de la valorisation organique, mais également de l’agro-urbanisme de l’aménagement des territoires et de la sécurité alimentaire, AUREA développe une expertise unique et complète afin d’accompagner l’agriculture dans sa transition agro-écologique.
201 to 500 staff
Bioc3
BioC3 is a French biotech startup that has created an innovative biocatalysis platform. This brings standardized and highly efficient reaction cascades thanks to stabilized enzymes. The reactions take place in water at ambient temperature and atmospheric pressure, using carbon sources that are renewable. No polluting by-product is generated.
1 to 10 staff
Biomeca
A deep expertise in Biomechanics and Surface Analysis in Life Sciences Living systems must be considered as physical systems. Unravelling the physical mechanisms underlying complex biological processes and diseases remains one of the greatest challenges in modern biology. At BioMeca®, we believe the starting point is to provide a quantitative physical description of biological samples. This approach enables a deeper understanding of biological processes and drives innovation across health, cosmetics, and biotechnology. Based in Lyon, BioMeca® is an expert in biomechanics and mechanobiology, specializing in high-resolution structural and mechanical characterization of biological samples across multiple scales: • Tissues, explants (ex vivo), and cells 🧫 • Subcellular structures and organelles • Molecules such as DNA and proteins 🧬, down to sub-molecular resolution We combine advanced methodologies to provide unique insights: • EASYSTIFF®: proprietary device for biomechanical characterization of skin and tissues • AFM (Atomic Force Microscopy): nano- to micro-scale mechanical mapping • SHG (Second Harmonic Generation): label-free 3D imaging of collagen and tissue structures • SEM (Scanning Electron Microscopy): high-resolution surface morphology • Ex vivo models: functional analysis on human skin explants Our approaches are designed for in vitro, ex vivo, in situ, and in vivo studies, bridging the gap from fundamental research to real-world applications. Contact: sales@bio-meca.com
11 to 50 staff
Gataca Systems
At GATACA, we design and integrate advanced optical and imaging systems tailored to the most demanding industrial environments. We support engineers, R&D teams, and system integrators by combining cutting-edge photonic components with modular, intelligent solutions — from prototyping to full-scale deployment. Our areas of expertise include: Advanced machine vision and imaging Custom optical system integration for complex setups Modular upgrades for both new and existing microscopes 🧪 Techniques we integrate: Ring TIRF, FRAP, Photo-activation, Photo-ablation, Micropatterning, Single Molecule Super-Resolution, Live Confocal Super-Resolution, SPIM, Multichannel Detection (up to 4 channels), triple-output high-power laser launches. All combinations can be operated simultaneously. 🤝 Since 2025, GATACA is part of ATLENSYS, a European leader in industrial photonics. This alliance boosts our capabilities, strengthens our network, and enables us to deliver more value across Europe and beyond. Our mission: Make optical innovation concrete, scalable, and impactful for today’s most ambitious industries. Get in touch: info@gataca-systems.fr
1 to 10 staff
Imean
iMEAN is a bioinformatics company based in Toulouse (France) and active member of the industrial demonstrator TWB (Toulouse White Biotechnology). Expert in reconstructing in silico models of complex living organisms (e.g. High-Quality Genome Scale Metabolic Networks), iMEAN is the right digital partner to help facing the massive transition currently undergone by the industry. By combining complex mathematical models, disruptive algorithms and expertise in biology, iMEAN designs advanced digital organisms with high predictive power enabling superior understanding of complex living organisms. From a simple genomic data analysis to the reconstruction of a full genome scale metabolic network, iMEAN provides a wide range of tailor-made in silico services. Through virtual experimentations, iMEAN can not only enable higher productivity or increase product quality, but also- Reduce time and cost of process development - Help making robust predictions - Design innovative products - Reduce risks - And much more Partner up with iMEAN and start shaping the future with your own digital organism.
11 to 50 staff
Invectys
Invectys, Inc. is a privately owned clinical-stage company, headquartered in Houston, Texas, which is developing a new generation of First-in-Class products for cancer patients. Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc.(Houston) which is directing the clinical development of the Company’s lead HLA-G product. Since 2010, Invectys has raised over $60 million in private funds to develop its two innovative platforms of immunotherapy products which target “universal” tumor antigens.
11 to 50 staff
Iprasense
IPRASENSE revolutionizes cell analysis with innovative technologies for automated cell counting and real-time visualization, ideal for research and quality control.
1 to 10 staff
Normec Abiolab
Laboratoires d’analyses des eaux, de l’air et des aliments. Le groupe Normec Abiolab, dans sa conformation actuelle est le résultat de la volonté entrepreneuriale de ses dirigeants de faire émerger sur le plan national un réseau de laboratoires de proximité pour répondre aux attentes de ses clients nationaux et régionaux. Aujourd’hui, ce réseau comprend 13 laboratoires répartis à travers la France et la Suisse, soutenu par une équipe de 300 collaborateurs. Issue d’une structure associative scientifique, notre organisation a également pour vocation de contribuer au développement économique et social des régions où nous sommes présents, et de favoriser l’amélioration de la connaissance scientifique au travers des projets de recherche que nous animons ou que nous soutenons.
201 to 500 staff
Pk Med
PK MED is a pioneering French biotech company, privately owned and founded in 2019 in Lyon, France, with the backing of Truffle Capital, a leading European venture capital firm specializing in life sciences. Built around a dedicated team of passionate and seasoned experts in pharmaceutical sciences, drug delivery, and biomaterials design, PK MED combines innovation and expertise to develop cutting-edge solutions in healthcare. PK MED specializes in the development of innovative, custom-designed, injectable, and biodegradable micro-implants, leveraging its expertise to address critical healthcare challenges. Our focus lies in advanced drug delivery systems for rheumatology and pioneering cell-homing techniques to enhance the success of bone marrow transplantation. Driven by a commitment to unmet medical needs, PK MED has built a promising portfolio of early-stage projects targeting key therapeutic areas, including gout flares, osteoarthritis, and hemoglobinopathies
1 to 10 staff
